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Abstract. The objective of this work was to evaluate soy protein isolate (SPI) and
acylated soy protein (SPA) as spray-drying encapsulation carriers for oral pharmaceutical
applications. SPI acylation was performed by the Schotten–Baumann reaction. SPA, with an
acylation rate of 41%, displayed a decrease in solubility in acidic conditions, whereas its
solubility was unaffected by basic conditions. The drug encapsulation capacities of both SPI
and SPA were tested with ibuprofen (IBU) as a model poorly soluble drug. IBU-SPI and
IBU-SPA particles were obtained by spray-drying under eco-friendly conditions. Yields of 70
to 87% and microencapsulation efﬁciencies exceeding 80% were attained for an IBU content
of 20 to 40% w/w, conﬁrming the excellent microencapsulation properties of SPI and the
suitability of the chemical modiﬁcation. The in vitro release kinetics of IBU were studied in
simulated gastrointestinal conditions (pH 1.2 and pH 6.8, 37°C). pH-sensitive release patterns
were observed, with an optimized low rate of release in simulated gastric ﬂuid for SPA
formulations, and a rapid and complete release in simulated intestinal ﬂuid for both
formulations, due to the optimal pattern of pH-dependent solubility for SPA and the
molecular dispersion of IBU in soy protein. These results demonstrate that SPI and SPA are
relevant for the development of pH-sensitive drug delivery systems for the oral route.
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INTRODUCTION
The oral route is the predominant and preferred drug
delivery route, due to several advantages relating to physi-
ological factors, patient compliance and economical produc-
tion methods (1). Research into innovative drug delivery
systems for this route has increased over the last 20 years,
largely driven by the growing need for novel drug delivery
systems to deal with the many newly developed chemical
entities with low solubility or poor permeation characteris-
tics, and the need to improve the delivery of existing drugs
(2,3). The development of pH-sensitive formulations is a
particularly relevant strategy for protecting both the gastric
mucosa and the active pharmaceutical ingredient (API),
controlling the delivery of the API to the gastrointestinal
tract and as an attractive alternative to coating (better safety
and fewer processing steps). Microencapsulation is one of
the most effective methods for drug delivery systems, as it
makes it possible to keep the API in an appropriate form in
the desired therapeutic range of concentrations, and to
optimize drug release (4). Spray-drying is a particularly
appropriate technique for microencapsulation. It is the most
widely used drying technology in the production of biophar-
maceutical formulations, with excellent properties, and it can
be used at the industrial scale, as a one-step microencapsu-
lation process (5,6).
The development of effective green or environmentally
friendly excipients is a key challenge in pharmaceutical
development that has triggered considerable interest in
natural polymers, due to their relative abundance, low cost,
and biodegradable and eco-friendly proﬁles (7). Proteins are
a biodegradable and biocompatible option with pertinent
functional properties for use as encapsulating materials for
APIs. Animal proteins have been investigated for several
years and have been found to have good solubility charac-
teristics, over a large pH range, and to be ﬂexible; they
therefore have good encapsulating properties (8), including
for pharmaceutical applications (9,10).
However, given the increasing numbers of vegetarians
and people avoiding dietary lactose, together with the need to
prevent potential health problems due to contamination (e.g.,
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bovine spongiform encephalopathy), plant proteins appear to
be a more appropriate alternative (11–13), although their
potential for use in pharmaceutical applications has yet to be
explored. Given its low cost, emulsifying properties, gelling
capacity, nutritional and technological properties, soy protein
isolate (SPI) is one of the most frequently studied plant
proteins and is already widely used as a carrier for food and
nutraceutical applications (14–18). However, only a few
studies have focused on the use of SPI for API encapsulation
and pharmaceutical applications, and even fewer have
considered chemical modiﬁcations to the protein to modulate
its functional properties (19).
In this study, we compared soy protein isolate (SPI) and
chemically modiﬁed soy protein (acylated, SPA), as spray-
drying encapsulation carriers for oral pharmaceutical appli-
cations. Acylation, by grafting fatty chains onto the free
amino groups of the protein, should modulate its pH
sensitivity, signiﬁcantly decreasing its solubility in acid media,
thereby reducing drug release in the stomach, and improving
bioavailability and absorption in the intestine. Indeed, the
attachment of hydrocarbon chains may modify the charge and
structural properties of water-soluble proteins, increasing
their hydrophobicity and improving protein afﬁnity for
hydrophobic drugs and microencapsulation efﬁciency (20).
Ibuprofen, a BCS (Biopharmaceutical Classiﬁcation
System) class II molecule, was chosen as the model hydro-
phobic drug for this study. Ibuprofen (IBU) is a non-steroidal
anti-inﬂammatory drug (NSAID) widely used as an analgesic,
anti-inﬂammatory, and anti-pyretic agent, with poor solubility
in water (21–23). The oral administration of IBU can lead to
gastrointestinal side effects, such as gastric erosion, peptic
ulcer, and bleeding (24,25). Therefore, there is a need for
innovative formulations providing better gastric protection
and more rapid release of ibuprofen in the intestine.
The ﬁrst part of this study involved the acylation of SPI
to modulate its pH sensitivity and the characterization of the
acylated soy protein (SPA) generated. We then assessed the
potential of SPI and SPA for drug encapsulation by spray-
drying, for various ibuprofen/protein ratios. Spray-drying
conditions were optimized so as to generate ibuprofen-soy
protein dried particles in a single step. The microparticles
obtained were characterized on the basis of their shape
(SEM observations), size (laser granulometry), microencap-
sulation rate, and efﬁciency. The in vitro release kinetics of
IBU were determined in simulated gastrointestinal condi-
tions, at pH 1.2 and pH 6.8 and 37°C. The encapsulated IBU
was studied by X-ray diffraction (XRD) and thermogravi-
metric analysis (TGA).
MATERIALS AND METHODS
Materials
SPI (90% pure) was purchased from Solae Belgium NV
(Ieper, Belgium). Ibuprofen (100% pure) was purchased from
BASF Corporation (USA). NaOH, 37% HCl, dodecanoyl
chloride, acetonitrile (HPLC grade), and pepsin porcine
gastric mucosa tested according to European Pharmacopeia
9.2 (Ph. Eur.) were purchased from Sigma (Saint-Quentin
Fallavier, France).
SPI Characterization
The proximate composition of SPI was determined,
including moisture, ash, protein, and lipid contents. Moisture
and ash contents were obtained with the standard AOAC
methods (26). Ash content was determined gravimetrically,
by incineration at 550°C, and moisture content was deter-
mined by drying samples to a constant weight at 105°C.
Protein content was determined by the Kjeldahl method (N ×
6.25) (27) and lipid content by conventional Soxhlet extrac-
tion in cyclohexane for 6 h. Total carbohydrate content was
determined by subtracting the sum of the moisture, ash,
protein, and lipid contents from the total mass (27). Proxi-
mate analysis was carried out in triplicate.
The amino acid proﬁle of SPI was determined on a
Biochrom 30 amino acid analyzer (Serlabo Technologies,
Entraigues sur la Sorgue, France).
Acylation of Soy Proteins
Acylated soy protein isolate (SPA) was prepared by the
Schotten–Baumann reaction (Fig. 1), as described by
Nesterenko et al. (28). Dodecanoyl chloride (C12) chains
were grafted onto the free terminal amine or lysine groups of
SPI. This reaction was performed in water and was catalyzed
by sodium hydroxide (pH 10), at 50°C for 180 min, with a
NH2/C12 molar ratio of 1/2. The product was lyophilized and
stored at 4°C.
The acylation rate (%) was evaluated by determining the
number of functional amine groups by the OPA method (29).
Protein Solubility Profile
Protein solubility proﬁle was determined as described by
Zheng et al. (30). Protein samples (SPI and SPA) were
prepared in deionized water (3% w/w) and the pH of the
mixture was adjusted to 1.0–10.0 with 4 M NaOH or 4 M HCl,
as appropriate. Each sample was stirred for 1 h at 37°C and
centrifuged at 10000×g for 15 min (Sigma Laborzentrifugen,
Osterode, Germany). The soluble protein content in the
supernatant was determined by the Kjeldahl method (tripli-
cate). Protein solubility (S) was calculated as follows:
S %ð Þ ¼ protein weight in the supernatant=total protein weight in solution
 100
Microencapsulation Process
Preparation of Protein/Ibuprofen Solutions
Various ratios of SPI or SPA to IBU were tested: 90/10,
80/20, and 60/40. The solutions were prepared as follows:
the protein (acylated or not) was dissolved in deionized
water (8% w/w) at room temperature, with magnetic
stirring. The pH was then adjusted to 8 (with 2 M NaOH)
to dissolve ibuprofen, with magnetic stirring for 30 min. The
solutions were also stirred mechanically at 500 rpm for
30 min. High-pressure homogenization was carried out with
an APV Systems homogenizer (Albertslund, Denmark), at
50 MPa with double circulation, and to enhance both the
stability of the solution and the encapsulation properties of
the proteins (31).
Spray-Drying
A Mini Spray Drier B-290 (Büchi, Flawil, Switzerland)
was used to spray 200 mL of solution under the following
conditions: inlet air temperature 120 ± 4°C and outlet air
temperature 74 ± 4°C, drying air ﬂow rate of 470 L/h, liquid
feed ﬂow rate of 0.33 L/h, and 100% aspiration. Microparti-
cles were collected and stored at 4°C.
Spray-drying yield (%) was calculated as follows:
Spray−drying yield %ð Þ ¼Mp=MSPþIBU  100
where Mp is the mass of collected powder and MSP + IBU
is the initial mass of solid content in the solution, including
soy protein (acylated or not) and ibuprofen.
HPLC Analysis
Ibuprofen concentration was measured with a HPLC
system equipped with a reverse-phase column (Phenomenex
Gemini® 5 μm C18 110 Å, 250 × 4.6 mm) and a precolumn
ﬁlled with the same phase. The system consists of a Dionex
P680 quaternary pump, a Dionex ASI-100 autosampler, an
UltiMate 3000 thermostat-controlled column compartment
and a Thermo Scientiﬁc Ultimate 3000 UV-DAD detector.
UV detection was performed at 222 nm. The mobile phase
was a 60:40 (w/w) mixture of 0.1 M sodium acetate (pH 7)
and acetonitrile.
The microparticles (10 mg) were dissolved in 50 mL of
mobile phase and sonicated for 10 min, then magnetically
stirred for 20 min. All samples were passed through cellulose
acetate (CA) ﬁlters with 0.45 μm pores and analyzed, in
triplicate, by HPLC.
The amount of ibuprofen in the microparticles was
determined from a calibration curve (ibuprofen concentration
range 0.05–1 mg/mL, in the mobile phase). For the in vitro
release study, two different ibuprofen calibration curves were
used to determine the amount of ibuprofen, depending on
pH: pH 1.2 with pepsin (ibuprofen concentration range
0.0005–0.02 mg/mL) and pH 6.8 (ibuprofen concentration
range 0.003–0.2 mg/mL).
Microencapsulation Efficiency and Microencapsulation Rate
Microencapsulation efﬁciency (MEE) and microencap-
sulation rate (MER) were calculated as follows:
MEE ¼ IBUexp=IBUtheo  100
where IBUexp is the amount of ibuprofen in microparticles,
determined by HPLC, and IBUtheo is the amount of
ibuprofen theoretically introduced in the initial solutions.
MER ¼ mIBU=mm  100
where mIBU is the estimated mass of ibuprofen in the
microparticles and mm is the mass of the analyzed micropar-
ticle sample.
Microparticle Characterization
Microparticle Size Distribution
Microparticle volume diameters (D4,3) were determined
by laser diffractometry with a Sirocco 2000 apparatus
(Malvern Instruments Ltd., Worcestershire, UK), using a
refractive index of 1.52 and a dispersion air pressure of 4 bars.
Morphology
The morphology (internal and external) of the micro-
particles was analyzed by scanning electron microscopy
(SEM) with a LEO435VP scanning electron microscope
(LEO Electron Microscopy Ltd., Cambridge, UK) operating
at 10 kV. The microparticles were deposited on conductive
double-faced adhesive tape and sputter-coated with silver.
In Vitro Release Kinetics
Drug release experiments were conducted with models
SPI/IBU (90/10) and SPA (90/10). The studies were per-
formed under sink conditions, in ﬂow-through cells (Sotax
CE6), as recommended by the European Pharmacopeia 9.2
(Ph. Eur.). Simulated gastrointestinal ﬂuids (SGF and SIF)
were used in the closed system (300 or 100 mL of dissolution
media, at pH 1.2 to simulate gastric conditions and pH 6.8 to
simulate conditions in the intestine). The dissolution media
were prepared as recommended by Ph. Eur.: simulated gastric
ﬂuid (SGF) at pH 1.2, with 0.32% pepsin (w/v), and simulated
intestinal ﬂuid (SIF) at pH 6.8. The cells were maintained at
37°C, under a constant ﬂow rate of 8 mL/min. Drug release
was followed by sampling 1 mL (n = 3) of the medium, at
predeﬁned time intervals, for up to 2 h. After each sampling,
1 mL of pure medium was added in order to maintain sink
conditions. The amount of drug released at each time point
was determined by the HPLC-UV method described above.
X-ray Diffraction
The powder crystallinity of ibuprofen, SPI, SPA, micropar-
ticles, and physical mixtures was assessed by X-ray powder
diffraction (EQUINOX 1000, France) at room temperature
with a Co target at 30 mA and 30 kV, in the region of 5°≤ 2θ≤
40°, with an angular increment of 0.02°.s−1 (32).
Fig. 1. Acylation via Schotten–Baumann reaction
Thermogravimetric Analysis
TGA of ibuprofen, and ibuprofen/protein physical mix-
tures and microparticles was carried out with an ATG/ETD
Q600 from TA Instruments (Newcastle, USA) at a linear
heating rate of 10°C/min, under air ﬂow, from 20 to 600°C.
Statistical Analysis
All analyses were carried out in triplicate and the data
collected were analyzed by one-way ANOVA with a conﬁ-
dence level of 0.95 and Tukey-Kramer multiple mean
comparisons in the MINITAB Release 17 statistical package
(Minitab Inc., USA).
RESULTS AND DISCUSSION
Before chemical modiﬁcation and evaluation, the com-
position of SPI was determined, to check that acylation was
feasible.
SPI Composition
SPI was found to consist predominantly of protein
(87.6%), but it also contained 0.4% lipids, 5.3% ash, 1.4%
carbohydrates, and 5.4% moisture. Its amino acid composi-
tion (Fig. 2) was determined. The protein chains consisted
essentially of 17 amino acids, with two amino acids, glutamic
acid (17.8%), and aspartic acid (11.6%), predominating, a
feature characteristic of plant proteins (15). The high levels of
carboxyl groups in these plant proteins should confer good
solubility in basic conditions. SPI also contained relatively
high levels of lysine (6.3%), within the normal range for the
proteins of leguminous plants (33). The amino group of lysine
can take part in various chemical reactions involving the
formation of amino bonds. SPI is, therefore, particularly
suitable for chemical modiﬁcations, such as acylation.
SPI Acylation
SPI was acylated with dodecanoyl chloride, a cheap,
biosourced reagent, which has been shown to improve the
encapsulation properties of SPI more effectively than
octanoyl and hexadecanoyl chlorides (28). A NH2/C12 molar
ratio of 1/2 was used to obtain a sufﬁciently high acylation
ratio (41%).
The attachment of alkyl chains should increase the
surface hydrophobicity of the protein chains, and greater
amphiphilicity induced should have an impact on protein
solubility and protein/drug interactions. The efﬁciency of this
chemical modiﬁcation was checked by comparing SPI and
SPA solubility proﬁles.
SPI and SPA pH Solubility Profiles
The pH solubility proﬁles of SPI and SPA were
compared (Fig. 3). The pH sensitivity of proteins is deter-
mined by the presence of acidic and basic groups in their
amino acid chains, which groups can accept or release
protons, depending on the pH of the medium (34). The
solubility curve of SPI was U-shaped, like those of most plant
proteins. Both proteins had a minimal solubility around pH
4–5, corresponding to their isoelectric point. At lower pH
values, the protonation of amino groups increased SPI
solubility, whereas acylation, which decreased the number of
available lysine cationic ammonium groups, prevented this
phenomenon (35). At pH values above 6, the carboxylic
groups of glutamic and aspartic acids were in their sodium
carboxylate form, increasing the solubility of both proteins. In
basic conditions (pH 8–10), the solubility proﬁles of the two
proteins were similar, with about 60% solubility, sufﬁcient for
effective microencapsulation (28), although SPA appeared to
be slightly less soluble than SPI, probably due to the presence
of lipophilic fatty chains.
These results demonstrate the efﬁcacy of the chemical
strategy developed: acylation greatly decreases protein solu-
bility in acidic conditions, without signiﬁcantly modifying the
maximal solubility in basic conditions.
Both SPI and SPA have been tested as potential carriers
for encapsulating IBU via spray-drying, in optimized exper-
imental conditions (28).
Microencapsulation Results
The properties of loaded spray-dried microparticles are
presented in Table I.
Fig. 2. Amino acid composition of soy protein isolate
Spray-drying yields of 70 to 87% were obtained. These
values are higher than those previously reported for micro-
encapsulation with plant proteins, ranging from 50 to 70%
(28,36). The spray-drying yields obtained in this study,
reaching a maximum of 80%, even for high ibuprofen ratios,
are very promising in terms of the industrial feasibility of this
process.
High MEE values (systematically greater than 80%)
were obtained for both proteins and for all soy protein/IBU
ratios, conﬁrming the excellent microencapsulation properties
of SPI and the suitability of the chemical modiﬁcation based
on acylation. However, SPI- and SPA-loaded microparticles
behaved differently.
For SPI-loaded microparticles, an increase in the pro-
portion of IBU (SPI/IBU ratio changing from 90/10 to 60/40)
leads to a decrease in MEE from 92 to 82%. Similar results
were reported in several previous studies on SPI (37,38), and
on other natural polymers, such as modiﬁed starch (39). In
these studies, the decrease in MEE was explained principally
by an increase in total solid content. In this study, increase in
the proportion of ibuprofen also resulted in a higher total
solid content. However, the decrease in MEE may also be
related to the hydrophobicity of ibuprofen, preventing
effective protection by SPI when the protein/IBU ratio was
too low (high amount of IBU).
By contrast, MEE increased with decreasing SPA/IBU
ratio, reaching 94% for SPA microparticles with a SPA/IBU
ratio of 60/40. The grafting of hydrophobic hydrocarbon
chains onto the protein probably enhanced the afﬁnity of
the acylated proteins for the hydrophobic core, even for
high ibuprofen contents. Previous studies reported similar
results (36,40), for various plant proteins, from soy, sun-
ﬂower, and rapeseed, for example, conﬁrming the suitability
of acylation for improving the encapsulation properties of
plant proteins.
Microparticle moisture content was between 1.4 and
3.7%, ensuring microbiological stability (41). The SPI-loaded
microparticles had a higher moisture content than the SPA-
loaded microparticles, due to the greater hygroscopy of
unmodiﬁed proteins. Similarly, highly loaded microparticles
had a lower moisture content, due their higher content of
ibuprofen, a hydrophobic drug.
Microparticles were between 3.5 and 5.8 μm in diameter,
except for the SPI 60/40 sample, for which some aggregates
were observed, making it difﬁcult to determine the size of the
microparticles correctly. These values are consistent with
those expected for spray-dried microspheres (31).
Morphology
The morphology of the microparticles was observed by
SEM. Some representative micrographs are displayed in
Fig. 4. The powder consisted of spherical particles with a
smooth surface, without ﬁssures or cracks, which protected
the ibuprofen well. An uneven shrinkage of the micropar-
ticles was observed, and such shrinkage is generally
Fig. 3. Solubility proﬁles of SPI and SPA at 3% w/w and 37°C
Table I. Properties of Loaded Spray-Dried Microparticles
Soy protein/ibuprofen
(% w/w)
Spray-drying
yield (%)
MEE
(%)*
MER
(%)*
Microparticle
size (D4,3) Μm
Moisture content
of microparticles (%)
SPI 80 – – 5.0 ± 0.1bc 5.1 ± 0.1a
SPA ND – – 4.2 ± 0.1bc 3.5 ± 0.3b
SPI 90/10 82 92.6 ± 9.3a 9.3 ± 0.9d 3.5 ± 0.2c 3.7 ± 0.1b
SPI 80/20 87 84.1 ± 3.6a 16.8 ± 0.7c 4.4 ± 0.3bc 2.3 ± 0.1e
SPI 60/40 80 81.9 ± 2.8a 32.6 ± 1.1b 19.1 ± 2.0a 3.2 ± 0.1c
SPA 90/10 70 87.4 ± 3.7a 8.7 ± 0.4d 4.3 ± 0.1bc 3.7 ± 0.1b
SPA 80/20 81 86.6 ± 4.5a 17.3 ± 0.9c 4.5 ± 0.1bc 2.8 ± 0.1d
SPA 60/40 87 93.9 ± 10.2a 37.6 ± 4.1a 5.8 ± 0.1b 1.4 ± 0.1f
Superscripts with the same letters in the same column were not signiﬁcantly different P > 0.5 (Tukey-Kramer multiple mean comparisons)
ND not determined
*Determined by HPLC
associated with the drying and/or cooling step(s) (37). The
external structure had wrinkled surface, typical of spray-
dried microparticles with a high protein content (42), but
no signiﬁcant differences according to the protein or
ibuprofen/protein ratio were observed. The internal struc-
ture revealed no evident porosity in the matrices, but
thinner shells were observed for highly loaded microparti-
cles (60/40 protein/IBU ratio). Moreover, no free drug
crystals were observed even for high IBU encapsulation
rates.
The size of the microspheres, from 1 to 9 μm, conﬁrmed
the values obtained by laser granulometry.
In Vitro Release Studies
IBU, a BCS (Biopharmaceutical Classiﬁcation System)
class II molecule, was chosen as the model drug for
encapsulation in SPI and SPA microparticles. The absorption
of BCS class II drugs (characterized by low solubility in water
and high permeation) can be signiﬁcantly improved by
optimizing the formulation so as to ensure that the drug
remains solubilized at the absorption site (43). This study
investigated whether SPI and SPA could be used to improve
the delivery of this poorly soluble drug with gastric side-
effects.
The effect of encapsulation in SPI and SPA microparti-
cles on the solubility of ibuprofen was assessed in dissolution
studies performed in vitro in sink conditions, with SPI and
SPA microparticles loaded with various amounts of IBU
(from 10 to 40%) in USP buffers at pH 1.2 or 6.8 USP, for 2 h
at 37°C. The dissolution proﬁles of IBU in two ibuprofen-
loaded preparations, SPI 90/10 and SPA 90/10, are presented
in Fig. 5. IBU release kinetics varied considerably with the
pH of the medium.
In acidic conditions (i.e., in simulated gastric ﬂuid
(SGF)) in the presence of a gastric enzyme (pepsin), a
slow release proﬁle was obtained for the IBU encapsu-
lated in microparticles of SPA or SPI, with 28.0 ± 4.3 and
42.8 ± 4.4% IBU release, respectively, within the ﬁrst hour.
Signiﬁcantly less IBU was released from the SPA 90/10
formulation than from the SPI 90/10 formulation
(p < 0.05).
Fig. 4. Scanning electron micrographs of microparticles. a SPI microparticles. b SPI/IBU 80/20. c SPI/IBU 60/40. d SPA. e
SPA/IBU 80/20. f SPA/IBU 60/40. Magniﬁcation of × 5000, scale bars 2 μm
Fig. 5. Ibuprofen release kinetics with SPI and SPA (at 90/10 ratio) in simulated gastric
ﬂuid (SGF) at pH 1.2 with pepsin and simulated intestinal ﬂuid at pH 6.8 (SIF)
These results may be considered to reﬂect the pH
sensitivity of SPI and SPA. Based on solubility data, pH had
a signiﬁcant effect on drug release from IBU-loaded SPI
and SPA microspheres. Below the isoelectric point of SPI
and SPA (pH = 4.5–5), the conformation of the protein
chain resulted in a compact, shrunken structure and low
release rate. This effect was particularly marked for SPA,
which insolubility in acidic conditions was enhanced by
acylation. In such conditions, the observed release was
probably due to drug diffusion, as already reported for
whey proteins (44). However, the observed release levels
were higher than expected in SGF, as release was evaluated
in the presence of pepsin, a proteolytic enzyme. In this
context, the release mechanism involved a combination of
diffusion and erosion, for which the rate of release depends
on protein content (data not shown). This phenomenon was
limited in our case, as pepsin preferentially cleaves the
peptide bonds of aromatic amino acids (histidine, phenylal-
anine, tryptophan, and tyrosine) (34), of which there are
very few in SPI, as shown in Fig. 2. The pH sensitivity of
SPI and SPA made it possible to obtain pH-sensitive
proﬁles of IBU release kinetics compatible with the oral
administration of this drug.
In neutral conditions (i.e., in simulated intestinal ﬂuid
(SIF) without enzymes), the release rates were faster, with
almost 100% of the IBU released within 90 min for both SPA
and SPI (99.1 ± 3.9 and 96.1 ± 1.8%, respectively). At pH 6.8,
the 90/10 ratio curves for SPA and SPI were similar, with a
release of at least 50% of the encapsulated IBU within the
ﬁrst 30 min. These results for SIF may be partly explained by
the solubility of SPI and SPA, and, thus, the dissolution of
particles at pH 6.8, but remain surprising for a poorly soluble
crystalline drug as IBU.
We decided to explore the interactions of IBU with SPI
and SPA, which may have a major inﬂuence on drug solubility
or thermal stability, and, consequently, on drug delivery
performance and bioavailability.
The possible interaction between the drug (IBU) and the
carrier (SPI and SPA) was investigated, with a view to
explaining the results for dissolution in SIF, by characterizing
the prepared microparticles, ibuprofen alone, and physical
mixtures, by XRD and TGA. An absence of characteristic
peaks/transitions of the drug after processing or a shifting of
those peaks, on the XRD pattern or the TGA thermogram,
indicates changes in the characteristics of the drug or the
possibility of drug-carrier interactions (45).
X-ray Diffraction
The X-ray diffraction patterns of IBU were compared with
those of IBU-SPI or IBU-SPA physical mixtures and micropar-
ticles, for each protein/IBU ratio tested. The X-ray diffraction
patterns of IBU, SPI, and of the 60/40 SPI/IBU physical mixture
and microparticles are presented in Fig. 6. The powder X-ray
diffractogramof IBUhas sharp peaks at diffraction angles 2θ = 6°,
16°, 17°, 19°, 20°, and 22°, showing a typical crystalline pattern
(23). SPI powder was semicrystalline, with two major peaks (32).
Fig. 6. DR-X patterns of ibuprofen, SPI, microparticles, and physical mixture of SPI/IBU 60/40
Fig. 7. TGA curves of IBU, SPI, physical mixture, and microparticles of SPI/IBU 60/40
All the major characteristic crystalline peaks of IBU were also
observed in the physical mixture, but were barely detectable in
microparticles, suggesting that the IBU was present in an
amorphous state in the microparticles. Similar results were
reported for IBU encapsulation with gelatin by spray-drying
(32) or riboﬂavin encapsulation with soy/zein protein (15). Our
results suggest that the combination of soy protein and spray-
drying led to a change in the crystallinity state of IBU, from a
crystalline to an amorphous form. Similar behavior was observed
for SPA, conﬁrming that acylation has no impact on the
encapsulation properties of soy protein at neutral pH.
Spray-drying is one of the most widely used solvent
evaporation procedures in the production of solid dispersions
and it often produces amorphous materials (46,47). The
amorphous solid state has the advantage of greater solubility
and, therefore, faster dissolution rates than crystalline mate-
rial, as no energy is required to break up the crystal lattice
during the dissolution process (48). This, together with the
solubility of SPI and SPA at neutral pH, may account for the
better dissolution of encapsulated IBU in SIF. This change in
crystalline state should increase the oral bioavailability of
IBU, by facilitating rapid absorption in the intestine (45).
Thermal Analysis
In addition to XRD, we also performed TGA studies.
TG mass loss curves were generated for IBU, SPI, and SPI/
IBU physical mixtures and microparticles with a 60/40 ratio of
protein to IBU (Fig. 7). Similar behavior was observed for
both proteins and for higher protein/IBU ratios. Ibuprofen
degradation occurred at about 170°C, with complete decom-
position at 230°C. Protein degradation did not start until
210°C for SPA, and 250°C for SPI, with mass loss maximal
(up to 70%) between 220 and 450°C, as generally observed
for plant proteins (28,36).
The small loss of mass observed at around 100°C on all
curves (other than that for IBU alone) can be attributed to
the evaporation of the residual water molecules present in
plant proteins (SPI and SPA).
A comparison of the curves for physical mixtures and
microparticles demonstrated the efﬁcacy of IBU protection by
spray-drying encapsulation. Indeed, thermal degradation began
at 170–175°C for physical mixtures, but not until 220°C for
microparticles, conﬁrming the improvement in the thermal
stability of IBU conferred by this microencapsulation process.
CONCLUSION
The results presented here demonstrate the suitability of
SPI and SPA as encapsulating materials for API by spray-
drying, particularly for delayed release oral applications.
Their advantages include pH sensitivity, the possibility of
incorporating high proportions of drug (up to 40%), and
excellent encapsulation efﬁciencies (greater than 80%). The
acetylation of SPI considerably decreases its sensitivity to
enzymes and acidity and, thus, greatly decreases drug release
in acidic conditions (simulated gastric ﬂuid). Furthermore, an
amorphous molecular dispersion of IBU was obtained,
improving the thermal stability of the drug and resulting in
its rapid dissolution at neutral pH (simulated intestinal ﬂuid).
Thus, SPI and SPA are promising excipients for the develop-
ment of hydrophobic drug delivery systems for the oral route.
ACKNOWLEDGMENTS
We would like to thank the Mexican Council of Science
CONACyT for providing ﬁnancial support, Yannick Thebault
and Cédric Charvillat from CIRIMAT for SEM and XRD
analyses, and Christine Rey-Rouch from LGC for TGA
analyses.
REFERENCES
1. Chen S, Guo F, Deng T, Zhu S, Liu W, Zhong H, et al. Eudragit
S100-coated chitosan nanoparticles co-loading tat for enhanced
oral colon absorption of insulin. AAPS PharmSciTech.
2017;18(4):1277–87. https://doi.org/10.1208/s12249-016-0594-z.
2. Bosselmann S, Williams RO III. Route-speciﬁc challenges in the
delivery of poorly water-soluble drugs. Formulating poorly
water soluble drugs. Berlin: Springer; 2012. p. 1–26.
3. O’Donnell KP, Williams RO III. Optimizing the formulation of
poorly water-soluble drugs. Formulating poorly water soluble
drugs. Berlin: Springer; 2012. p. 27–93. https://doi.org/10.1007/
978-1-4614-1144-4_2.
4. Mehta S, Kaur G, Verma A. Fabrication of plant protein
microspheres for encapsulation, stabilization and in vitro release
of multiple anti-tuberculosis drugs. Colloids Surf A.
2 0 1 1 ; 3 7 5 ( 1 ) : 2 1 9 – 3 0 . h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 /
j.colsurfa.2010.12.014.
5. Georgetti SR, Casagrande R, Souza CRF, Oliveira WP, Fonseca
MJV. Spray drying of the soybean extract: effects on chemical
properties and antioxidant activity. LWT - Food Sci Technol.
2008;41(8):1521–7. https://doi.org/10.1016/j.lwt.2007.09.001.
6. Ameri M, Maa Y-F. Spray drying of biopharmaceuticals:
stability and process considerations. Dry Technol.
2006;24(6):763–8. https://doi.org/10.1080/03602550600685275.
7. Ogaji IJ, Nep EI, Audu-Peter JD. Advances in natural polymers
as pharmaceutical excipients. Pharm Analytical Acta.
2012;3(1):1–16.
8. Can Karaca A, Low NH, Nickerson MT. Potential use of plant
proteins in the microencapsulation of lipophilic materials in
foods. Trends Food Sci Technol. 2015;42(1):5–12. https://doi.org/
10.1016/j.tifs.2014.11.002.
9. Bruschi ML, Cardoso MLC, Lucchesi MB, Gremião MPD.
Gelatin microparticles containing propolis obtained by spray-
drying technique: preparation and characterization. Int J Pharm.
2003;264(1–2) :45–55. https : / /doi .org/10.1016/S0378-
5173(03)00386-7.
10. Hsein H, Garrait G, Mumin MA, Beyssac E, Hoffart V.
Atomization of denatured whey proteins as a novel and simple
way to improve oral drug delivery system properties. Int J Biol
Macromol. 2017;105(Pt 1):801–9. https://doi.org/10.1016/
j.ijbiomac.2017.07.114.
11. Nesterenko A, Alric I, Silvestre F, Durrieu V. Vegetable
proteins in microencapsulation: a review of recent interventions
and their effectiveness. Ind Crop Prod. 2013;42(0):469–79.
https://doi.org/10.1016/j.indcrop.2012.06.035.
12. Reddy N, Yang Y. Potential of plant proteins for medical
applications. Trends Biotechnol. 2011;29(10):490–8. https://
doi.org/10.1016/j.tibtech.2011.05.003.
13. Tang C-H, Li X-R. Microencapsulation properties of soy protein
isolate and storage stability of the correspondingly spray-dried
emulsions. Food Res Int. 2013;52(1):419–28. https://doi.org/
10.1016/j.foodres.2012.09.010.
14. Gharsallaoui A, Roudaut G, Chambin O, Voilley A, Saurel R.
Applications of spray-drying in microencapsulation of food
ingredients: an overview. Food Res Int. 2007;40(9):1107–21.
https://doi.org/10.1016/j.foodres.2007.07.004.
15. Chen L, Subirade M. Elaboration and characterization of soy/
zein protein microspheres for controlled nutraceutical delivery.
Biomacromolecules. 2009;10(12):3327–34. https://doi.org/
10.1021/bm900989y.
16. González-Ferrero C, Irache J, González-Navarro C. Soybean
protein-based microparticles for oral delivery of probiotics with
improved stability during storage and gut resistance. Food
Chem . 2018 ; 239 : 8 79–88 . h t t p s : / / do i . o rg / 1 0 . 1 0 16 /
j.foodchem.2017.07.022.
17. Hadzieva J, Mladenovska K, Crcarevska MS, Dodov MG,
Dimchevska S, Geškovski N, et al. Lactobacillus casei encapsu-
lated in soy protein isolate and alginate microparticles prepared
by spray drying. Food Technol Biotechnol. 2017;55(2):173–86.
10.17113/ftb.55.02.17.4991.
18. Tang Z-X, Liang J-Y. Use of soy protein-based carriers for
encapsulating bioactive ingredients. Soy protein-based blends,
composites and nanocomposites. Hoboken: Wiley; 2017. p. 231–
49.
19. Caillard R, Petit A, Subirade M. Design and evaluation of
succinylated soy protein tablets as delayed drug delivery
systems. Int J Biol Macromol. 2009;45(4):414–20. https://
doi.org/10.1016/j.ijbiomac.2009.06.013.
20. Lazko J, Popineau Y, Legrand J. Soy glycinin microcapsules by
simple coacervation method. Colloids Surf B. 2004;37(1–2):1–8.
https://doi.org/10.1016/j.colsurfb.2004.06.004.
21. Abraham P, Indirani K, Desigamani K. Nitro-arginine methyl
ester, a non-selective inhibitor of nitric oxide synthase reduces
ibuprofen-induced gastric mucosal injury in the rat. Dig Dis Sci.
2005;50(9):1632–40. https://doi.org/10.1007/s10620-005-2908-y.
22. Wood DM, Monaghan J, Streete P, Jones AL, Dargan PI.
Fatality after deliberate ingestion of sustained-release ibupro-
fen: a case report. Crit Care. 2006;10(2):R44. https://doi.org/
10.1186/cc4850.
23. Liu Y, Wang X, Liu Y, Di X. Thermosensitive in situ gel based
on solid dispersion for rectal delivery of ibuprofen. AAPS
PharmSciTech. 2017; https://doi.org/10.1208/s12249-017-0839-5.
24. Yang L, Zhang B, Yi J, Liang J, Liu Y, Zhang L-M. Preparation,
characterization, and properties of amylose-ibuprofen inclusion
complexes. Starch - Stärke. 2013;65(7–8):593–602. https://
doi.org/10.1002/star.201200161.
25. Tamilvanan S, Sa B. In vitro and in vivo evaluation of single-
unit commercial conventional tablet and sustained-release
capsules compared with multiple-unit polystyrene microparticle
dosage forms of ibuprofen. AAPS PharmSciTech.
2006;7(3):E126–E34. https://doi.org/10.1208/pt070372.
26. International A. Ofﬁcial methods of analysis of AOAC Inter-
national. Ofﬁcial methods of analysis of AOAC International.
1995;Volume II.
27. Yew S-E, Lim T-J, Lew L-C, Bhat R, Mat-Easa A, Liong M-T.
Development of a probiotic delivery system from agrowastes,
soy protein isolate, and microbial transglutaminase. J Food Sci.
2011;76(3):H108–H15. https: / /doi .org/10.1111/ j .1750-
3841.2011.02107.x.
28. Nesterenko A, Alric I, Silvestre F, Durrieu V. Inﬂuence of soy
protein's structural modiﬁcations on their microencapsulation
properties: α-tocopherol microparticle preparation. Food Res
I n t . 2 0 1 2 ; 4 8 ( 2 ) : 3 8 7–9 6 . h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 /
j.foodres.2012.04.023.
29. Church FC, Swaisgood HE, Porter DH, Catignani GL. Spec-
trophotometric assay using o-phthaldialdehyde for determina-
tion of proteolysis in milk and isolated milk proteins 1. J Dairy
Sci. 1983;66(6):1219–27. https://doi.org/10.3168/jds.S0022-
0302(83)81926-2.
30. Zheng H-G, Yang X-Q, Tang C-H, Li L, Ahmad I. Preparation
of soluble soybean protein aggregates (SSPA) from insoluble
soybean protein concentrates (SPC) and its functional proper-
ties. Food Res Int. 2008;41(2):154–64. https://doi.org/10.1016/
j.foodres.2007.10.013.
31. Sharif HR, Williams PA, Sharif MK, Abbas S, Majeed H,
Masamba KG, et al. Current progress in the utilization of native
and modiﬁed legume prote ins as emuls iﬁers and
encapsulants—a review. Food Hydrocoll. 2017; https://doi.org/
10.1016/j.foodhyd.2017.01.002.
32. Li DX, Oh Y-K, Lim S-J, Kim JO, Yang HJ, Sung JH, et al.
Novel gelatin microcapsule with bioavailability enhancement of
ibuprofen using spray-drying technique. Int J Pharm.
2 0 0 8 ; 3 5 5 ( 1 – 2 ) : 2 7 7 – 8 4 . h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 /
j.ijpharm.2007.12.020.
33. Nielsen PM, Petersen D, Dambmann C. Improved method for
determining food protein degree of hydrolysis. J Food Sci.
2 00 1 ; 6 6 ( 5 ) : 6 4 2–6 . h t t p s : / / d o i . o rg / 1 0 . 1111 / j . 1 3 65 -
2621.2001.tb04614.x.
34. Maltais A, Remondetto GE, Subirade M. Soy protein cold-set
hydrogels as controlled delivery devices for nutraceutical
compounds. Food Hydrocoll. 2009;23(7):1647–53. https://
doi.org/10.1016/j.foodhyd.2008.12.006.
35. Gruener L, Ismond M. Effects of acetylation and succinylation
on the functional properties of the canola 12S globulin. Food
Chem. 1997;60(4):513–20. https://doi.org/10.1016/S0308-
8146(97)00016-2.
36. Wang Z, Ju X, He R, Yuan J, Wang L. The effect of rapeseed
protein structural modiﬁcation on microstructural properties of
pept ide microcapsules . Food Bioprocess Technol .
2015;8(6):1305–18. https://doi.org/10.1007/s11947-015-1472-5.
37. Deng XX, Chen Z, Huang Q, Fu X, Tang CH. Spray-drying
microencapsulation of β-carotene by soy protein isolate and/or
OSA-modiﬁed starch. J Appli Polym Sci. 2014;131(12):40399.
38. Tang C-H, Li X-R. Microencapsulation properties of soy protein
isolate: inﬂuence of preheating and/or blending with lactose. J
Food Eng. 2013;117(3):281–90. https://doi.org/10.1016/
j.jfoodeng.2013.03.018.
39. Rocha GA, Fávaro-Trindade CS, Grosso CRF. Microencapsu-
lation of lycopene by spray drying: characterization, stability
and application of microcapsules. Food Bioprod Process.
2012;90(1):37–42. https://doi.org/10.1016/j.fbp.2011.01.001.
40. Nesterenko A, Alric I, Violleau F, Silvestre F, Durrieu V. The
effect of vegetable protein modiﬁcations on the microencapsu-
lation process. Food Hydrocoll. 2014;41(0):95–102. https://
doi.org/10.1016/j.foodhyd.2014.03.017.
41. Mendanha DV, Ortiz SEM, Favaro-Trindade CS, Mauri A,
Monterrey-Quintero ES, Thomazini M. Microencapsulation of
casein hydrolysate by complex coacervation with SPI/pectin.
Food Res Int. 2009;42(8):1099–104. https://doi.org/10.1016/
j.foodres.2009.05.007.
42. Liu F, Chen Z, Tang C-H. Microencapsulation properties of
protein isolates from three selected Phaseolus legumes in
comparison with soy protein isolate. LWT-Food Sci Technol.
2014;55(1):74–82. https://doi.org/10.1016/j.lwt.2013.09.008.
43. Pouton CW. Formulation of poorly water-soluble drugs for oral
administration: physicochemical and physiological issues and
the lipid formulation classiﬁcation system. Eur J Pharm Sci.
2006;29(3–4):278–87. https://doi.org/10.1016/j.ejps.2006.04.016.
44. Hsein H, Garrait G, Tamani F, Beyssac E, Hoffart V. Denatured
whey protein powder as a new matrix excipient: design and
evaluation of mucoadhesive tablets for sustained drug release
applications. Pharm Res. 2017;34(2):365–77. https://doi.org/
10.1007/s11095-016-2067-1.
45. Zheng H, Zhou Z, Chen Y, Huang J, Xiong F. pH-sensitive
alginate/soy protein microspheres as drug transporter. J Appl
Polym Sci. 2007;106(2):1034–41. https://doi.org/10.1002/
app.26725.
46. Patel BB, Patel JK, Chakraborty S, Shukla D. Revealing facts
behind spray dried solid dispersion technology used for
solubility enhancement. Saudi Pharm J. 2015;23(4):352–65.
47. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as
strategy to improve oral bioavailability of poor water soluble
drugs. Drug Discov Today. 2007;12(23):1068–75. https://doi.org/
10.1016/j.drudis.2007.09.005.
48. Duarte I, Temtem M, Gil M, Gaspar F. Overcoming poor
bioavailability through amorphous solid dispersions. Ind Pharm.
2011;30:4–6.
